X
Apr 09, 2021 04:10 PM (GMT+8) · EqualOcean
On April 8, Baiji Shenzhou (Beijing) Biotechnology Co., Ltd. announced that the commercial production of Guangzhou biopharmaceutical production base was officially approved. The first 8000 liter production capacity approved for commercial production will be used for the production of PD-1 anti-tumor drug tirelizumab injection from now on, which is also the first biopharmaceutical factory approved for commercial production of anti-PD-1 antibody in Guangdong Province.